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expression also led to inflammatory responses and synap-
tic dysfunction. Taken together, this work demonstrates a 
toxic effect of C99 which could underlie some of the early-
stage anatomical hallmarks of Alzheimer’s disease pathol-
ogy. Our work also proposes molecular mechanisms likely 
explaining some of the unfavorable side-effects associated 
with γ-secretase inhibitor-directed therapies.
Keywords Alzheimer · C99 · Lysosomes · Autophagy · 
Aggregation · Triple-transgenic mouse · γ-Secretase 
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Introduction
Alzheimer’s disease (AD) is the most prevalent neurode-
generative disease and cause of dementia in elderly. His-
topathologically, it is characterized by the deposition of 
extracellular amyloid plaques and intraneuronal neurofi-
brillary tangles, as well as synaptic pathology and neurode-
generation [7]. Growing evidence supports that these alter-
ations are preceded and may be even caused by a defective 
endolysosomal/autophagic degradation [33, 36, 39, 43, 50]. 
Indeed, endolysosomal/autophagic anomalies are well-rec-
ognized early neuropathological features of AD, marked by 
enlarged endosomes, lysosomal alterations and progressive 
accumulation of autophagic vacuoles (AVs) [33–35, 39, 43, 
50]. It is also well established that endosomal-autophagic-
lysosomal (EAL) compartments constitute the main sites 
of proteolytic processing of the amyloid-β precursor pro-
tein βAPP [43] and that amyloidogenic species can accu-
mulate inside organelles of the EAL machinery [12, 20, 
24, 26, 62]. Moreover, the accumulation of the aggregate-
prone Aβ42 within EAL organelles was found to disturb 
normal EAL function, suggesting that it could be both a 
Abstract Endosomal-autophagic-lysosomal (EAL) dys-
function is an early and prominent neuropathological fea-
ture of Alzheimers’s disease, yet the exact molecular mech-
anisms contributing to this pathology remain undefined. 
By combined biochemical, immunohistochemical and 
ultrastructural approaches, we demonstrate a link between 
EAL pathology and the intraneuronal accumulation of the 
β-secretase-derived βAPP fragment (C99) in two in vivo 
models, 3xTgAD mice and adeno-associated viral-medi-
ated C99-infected mice. We present a pathological loop in 
which the accumulation of C99 is both the effect and cau-
sality of impaired lysosomal-autophagic function. The del-
eterious effect of C99 was found to be linked to its aggre-
gation within EAL-vesicle membranes leading to disrupted 
lysosomal proteolysis and autophagic impairment. This 
effect was Aβ independent and was even exacerbated when 
γ-secretase was pharmacologically inhibited. No effect was 
observed in inhibitor-treated wild-type animals suggest-
ing that lysosomal dysfunction was indeed directly linked 
to C99 accumulation. In some brain areas, strong C99 
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consequence and a cause of endolysosomal-autophagic 
dysfunction [43].
EAL dysfunction has been extensively described in 
transgenic mice displaying AD-like anatomo-pathol-
ogy [11, 13, 47, 51, 55, 61] including in the widely used 
3xTgAD mouse (APPSwe, TauP301L, PS1M146V) [10, 11, 
37]. It is also well known that this mouse model displays 
an early accumulating and particularly high intraneuronal 
amyloid-like immunostaining within the subiculum of the 
hippocampus, which was firstly accounted for Aβ [37]. Yet, 
we recently demonstrated that this staining corresponded 
to the β-secretase-derived fragment, C99 (βCTF) rather 
than to Aβ, which was only detected at low levels and at 
late stages in these mice [24]. We found that C99 accumu-
lated in enlarged cathepsin B-positive structures suggesting 
a link between C99 and EAL pathology [24]. In this work, 
we establish that C99 accumulation is the consequence of 
impaired lysosomal-autophagic degradation but that C99, 
in turn, also contributes to lysosomal dysfunction. Interest-
ingly, these effects of C99 were observed in the 3xTgAD 
mouse, in which C99 is generated by proteolytically APP 
processing, but also in a direct transgenic C99-expressing 
mouse. C99 fragments were found to aggregate within 
membranes of EAL vesicles, proposing that C99 induces 
autophagic-lysosomal dysfunction by interfering with EAL 
membrane integrity. The pharmacological inhibition of 
γ-secretase increased the levels of EAL-associated C99 and 
exacerbated pathology, clearly demonstrating a C99 dose-
dependent but Aβ-independent effect. Overall, our work 
demonstrates a detrimental loop in which aggregated C99 
contributes to anatomical hallmarks reminiscent of those 
occurring early in Alzheimer’s disease.
Materials and methods
Viral constructions
Virus production was performed following a protocol previ-
ously described [4]. Briefly, HEK293 cells were transfected 
with the adenovirus helper plasmid (pXX6), the AAV pack-
aging plasmid (rAAV2-rh10), and the AAV10 plasmid 
empty vector or encoding either human C99 or GFP under 
control of the synapsin-1 promoter (AAV-empty, AAV-
synC99 and AAV-synGFP). Viruses were produced, puri-
fied and vector titers were determined by real-time PCR 
and expressed as viral genomes per ml (vg/ml) [4].
Animals and in vivo drug treatment
3xTgAD (harboring PS1M146V, βAPPswe, and TauP301L 
transgenes) and non-transgenic (nonTg) mice [37] were 
generated from breeding pairs provided by Dr. LaFerla 
(Irvine, USA). 2xTgAD (PS1wt, βAPPswe and TauP301L) 
were produced by crossing 3xTgAD with nonTg mice, as 
described [38]. For AAV-mediated in vivo delivery, 1-day-
old C57BL6 mice (Janvier Labs., France) were injected 
with 4 µl of AAV virus (5.5 × 1012 vg/ml (viral genomes 
per ml)) into the left lateral ventricle, as described [21] 
and mice were analyzed at 2 months post-AAV delivery. 
5-month-old nonTg and 3xTgAD males or 2-month-old 
AAV-infected mice (males and females) were treated daily 
for 12 or 30 days with the γ-secretase inhibitor ELND006, 
referred to as D6 hereafter (30 mg/kg, Elan Pharmaceu-
ticals, San Francisco, USA) [9, 45] or with vehicle alone 
(methylcellulose/polysorbate 80, Sigma) via oral gav-
age, as described [24]. All experimental procedures were 
in accordance with the European Communities Council 
Directive of 24 November 1986 (86/609/EEC) and local 
French legislation.
Immunohistochemical analysis
Animals were deeply anesthetized with a lethal dose of 
pentobarbital and perfused transcardially with cold phos-
phate-buffered saline (PBS). Brains were fixed in 4 % 
Paraformaldehyde/PBS then embedded in paraffin and 
sliced (8 μm) or cut on a vibratome (50 μm). For FCA18, 
82E1, NU1, 4G8 and 6E10 staining, sections were treated 
with formic acid (90 % or 50 %/5 min for paraffin and 
vibratome sections, respectively). Sections were then incu-
bated at 4 °C overnight with primary antibodies (see sup-
plementary table) followed by Alexa Fluor-conjugated 
antibodies (Molecular Probes, 1:1000). Cathepsin B labe-
ling was amplified using the Vectorstain ABC kit (Vector) 
and streptavidin-Alexa594 (Molecular Probes, 1:1000). 
Nuclei were stained with DAPI (Roche, 1:20,000) and 
fluorescence was visualized using a confocal microscope 
(Fluoview10, Olympus). For DAB development, sections 
were incubated with HRP-conjugated secondary antibod-
ies (Jackson ImmunoResearch, 1/1000) followed by DAB 
substrate (DAB impact, Vector). Neuronal nuclei were 
then stained with cresyl violet. For quantitative analysis of 
lamp1 staining in AAV-empty and AAV-C99 brain slices, 
images were thresholded, converted to mask and analyzed 
using Particle Analysis ImageJ plugin.
Cell culture and experimental treatments
The human neuroblastoma cell line SH-SY5Y, naive or 
stably expressing APPswe or pcDNA3 (mock), previ-
ously described [40] was exposed to the following drugs 
for 16–20 h: D6 (50 nM to 5 μM, Elan Pharmaceuticals, 
San Francisco) in vehicle (methylcellulose/polysorb-
ate 80, Sigma), DAPT (5 μM in DMSO, Sigma), leu-
peptin (10 μM in H2O, Sigma), PADK (5 μM in DMSO, 
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Bachem), NH4Cl (10 mM in H2O, Sigma), pepstatin A 
(10 μM in EtOH, Enzo Life sciences), smer28 (50 μM 
in DMSO, Sigma) and bafilomycin A1 (50 nM in H20, 
Sigma). Some cells were transfected with GFP-LC3 
(Addgene) using Lipofectamine 2000 according to stand-
ard protocols. Other cells were infected with lentiviruses 
(LV) encoding mouse cathepsin B (LV-mCatB-FUGW2) or 
control (LV-FUGW2) [32] and polyclonal cell lines stably 
expressing mCatB (naive SH-SY5Y or APPswe-SH-SY5Y 
cells) were obtained. For immunocytochemical experi-
ments of C99 expression, COS-7 cells were transfected 
with C99 using Lipofectamine 2000.
Immunocytochemistry
Cells were immunostained with α-APPct (1:5000) and 
α-lamp-1 (E-5, 1:100) or α-cis-golgi (GM130, Cell signal-
ing, 1:400) followed by Alexa Fluor-488 or Alexa Fluor-594 
conjugated antibodies (1:1000, Molecular Probes). Nuclei 
were stained with DAPI (1:20,000, Molecular probes). 
Other cells were incubated 30 min with Lysotracker-Red 
DND-99 (1:20,000, Invitrogen) at 37 °C, fixed with PFA 
4 % and stained with DAPI. Images were acquired using 
an inverted confocal microscope (Fluoview10, Olympus, 
France).
In vitro degradation assay
Recombinant C99 (C100-flag), previously described [49], 
was incubated in the absence or presence of purified cath-
epsin B from human placenta (5, 10 or 50 ng, Sigma) in 
100 mM sodium acetate pH 5 buffer containing 1 mM 
EDTA and 8 mM cysteine at 37 °C during 60 min, then 
analyzed on Tris-Tricine 16 % acrylamide gels as described 
below. C100flag was revealed using an anti-flag antibody 
(M2, 1:5000, Sigma).
Electron microscopy
Cells were fixed 20 min with 2.5 % glutaraldehyde/phos-
phate buffer 0.1 N (pH 7.4). Mice were anesthetized with 
a lethal dose of pentobarbital and perfused transcardially 
with ice cold physiological saline followed by 2 % glutar-
aldehyde/cacodylate buffer 0.1 M (pH 7.4). The brain was 
sliced (200 μm) on a vibratome and 2 mm cubes from the 
subiculum were microdissected under binoculars and post-
fixed in osmium tetroxide (1 % in cacodylate buffer 0.1 M). 
The tissue was embedded in Epon resin (EMS) and 80 nm 
ultrathin sections were contrasted with uranyl acetate and 
lead citrate and visualized using a JEM 1400 electron 
microscope operating at 100 kV equipped with a Morada 
SIS camera.
Preparation of brain fractions
Dissected hippocampi of vehicle or D6-treated 3xTgAD or 
nonTg mice, or hemispheres from AAV-injected mice, were 
homogenized in RIPA buffer (Tris 50 mM; pH 7.4 contain-
ing NaCl (150 mM), EDTA (1 mM), Triton X100 (1 %), 
deoxycholate (0.5 %), SDS (0.1 %) and protease inhibitor 
cocktail (Sigma) and soluble and insoluble fractions were 
prepared as described [24]. Synaptosomal and microsomal 
enriched fractions were prepared from hippocampi of vehi-
cle or D6-treated 3xTgAD mice. Tissue was homogenized 
in 0.32 M sucrose containing protease inhibitor cocktail 
(Sigma), centrifuged twice at 850×g/5 min and the collected 
supernatants were centrifuged twice at 12,000×g/20 min. 
The obtained pellet (“synaptomal fraction”) was resus-
pended in Hepes 4 mM/EDTA. The supernatant was centri-
fuged at 20,000×g/1 h to obtain the “microsomal fraction”.
SDS/PAGE and western blot analyses
Proteins were separated on 16 % Tris-Tricine gels (for 
APP-CTFs, cathepsin B and LC3) or 10 % Tris–glycine 
gels (for βAPP p62 and actin) and transferred to nitrocel-
lulose membranes. After probing with primary antibodies 
(see supplementary table), immunological complexes were 
revealed with HRP-conjugated antibodies (Jackson Immu-
noResearch, 1/10,000) followed by electrochemilumines-
cence (Supersignal West Pico/West Maximum Sensitivity 
chemiluminescence substrate, Thermo Scientific, France). 
Peak height of signal intensities from protein bands were 
quantified with ImageJ software.
Quantification of human Aβ
Aβ40 and Aβ42 levels were quantitatively detected in solu-
ble and insoluble fractions (see above) of mice hippocampi 
(for 3xTgAD mice) or hemispheres (for AAV-synC99 
mice) using sandwich ELISA kits detecting human Aβ40 
and Aβ42, respectively (Biosource, Invitrogen, France). 
Absorbance was read at 450 nm using a spectrophotometer.
In vitro cathepsin B activity assay
Cells were lysed mechanically in homogenization buffer 
(250 mM sucrose, 1 mM EDTA, 5 mM Hepes pH 7.4). 
The cell suspension was centrifuged at 850×g/5 min and 
the supernatant was centrifuged at 20,000×g/90 min. 
The pellet (membrane enriched fraction) was resus-
pended in Tris–HCl (10 mM, pH 7.5). To monitor cath-
epsin B (CatB) activity, 60 µg of protein extracts were 
incubated in acetate buffer (25 mM, pH 5.5, 100 µl 
and 8 mM l-cysteine HCl) containing CatB substrate 
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(CBZ-Arg-Arg-7-Amido-4-methylcoumarin, 100 µM, 
Sigma) in the absence or presence of leupeptin (10 µM, 
Sigma). Specific CatB activity corresponds to the leupep-
tin-sensitive fluorescence recorded at 320 nm (excitation) 
and 420 nm (emission) using a fluorescence plate reader 
(FLUOstar Omega, BMG Labtech, France). CatB activity 
was calculated as the slope in the linear range correspond-
ing to the initial 30 min.
Electrophysiological recordings
LTP measurements were performed by E-Phy-Science, 
Sophia Antipolis, France. 2-month-old AAV-empty, vehicle 
or D6-treated AAV-C99 females, were anesthetized with 
isoflurane and decapitated. Stimulations were delivered 
in CA1 fibers in the alveus and field excitatory postsyn-
aptic potential (f-EPSP) were recorded from the subicular 
pyramidal neurons in the middle portion of the subiculum. 
The LTP-induction protocol consisted of four trains of 100 
stimuli at 100 Hz repeated every 20 s, as described [41].
Statistical analysis
Statistical analysis was performed with PRISM software 
(Graph-Pad Software, San Diego, CA, USA) by using a 
non-parametric two-tailed Mann–Whitney U test for pair-
wise comparisons or the two-way ANOVA test followed 
by either the Tukey’s post hoc test for multiple compari-
sons or the Dunnett post hoc test when comparison to con-
trols. All data are expressed as the mean ± SEM. Differ-
ences were considered significant at *p < 0.05, **p < 0.01, 
***p < 0.001.
Results
3xTgAD and 2xTgAD mice display early 
and progressive C99 accumulation within enlarged 
cathepsin B and lamp1 positive structures
We previously demonstrated that the β-secretase-derived 
APP C-terminal stub C99 corresponded to the early appear-
ing and accumulating intracellular label in the subiculum 
of 3xTgAD mice [24]. This label could be detected with 
N-terminal directed antibodies including the β-secretase-
mediated cleavage-specific antibodies FCA18 [3] and 
82E1 [19] known to recognize both Aβ and C99. A similar 
accumulating intraneuronal FCA18-immunostaining was 
observed in double transgenic (2xTgAD) mice harboring 
APPswe and TauP301L but wild-type presenilin1 [24] (Suppl. 
Figure 1a). Interestingly, in the two strains this intracel-
lular staining (Suppl. Figure 1a) and C99 levels (Suppl. 
Figure 1c, d) increased similarly with age, while only 
3xTgAD mice produced extracellular plaques at late ages 
that were stained with both FCA18 (Suppl. Figure 1a) and 
anti-Aβ42 (α-Aβ42) (Suppl. Figure 1b). The detection of 
very few extracellular Aβ plaques in situ in aged 2xTgAD 
mice was corroborated by the absence or very low detect-
able levels of both Aβ40 and Aβ42 measured by ELISA 
(Suppl. Figure 1e). Overall, these data indicated that C99 
accumulation did not correlate with Aβ load and there-
fore could not be accounted for altered γ-secretase pro-
cessing alone. In situ immunolabeling with 82E1 revealed 
that C99 accumulated in intraneuronal organelles positive 
for the lysosomal enzyme cathepsin B (Fig. 1a) and sug-
gested a link between C99 accumulation and defective 
lysosomal clearance. In young 3xTgAD mice (3 months 
of age), the majority of the neurons displayed numerous 
small-sized cathepsin B puncta (Fig. 1a, arrows), but some 
neurons also presented enlarged cathepsin B structures 
which were positive for C99 (Fig. 1a, arrowheads). Simi-
lar results were obtained with an antibody directed against 
the endosomal-lysosomal membrane-associated protein 
lamp1, and the number and size of these structures were 
high in both 14-month-old 2AD and 3AD mice (Fig. 1b). 
The large size of these structures proposed that many of 
them corresponded to endo- or autolysosomes rather than 
to lysosomes and would support impaired lysosomal-
autophagic-mediated C99 degradation in both 2xTgAD and 
3xTgAD mice. In agreement, electron microscopy revealed 
an increased number of dense autophagic vesicles in brains 
from both of these mice, as compared to non-transgenic 
mice (Fig. 1c, red arrowheads). These autophagic vacuoles 
corresponded to both small and very dark autolysosomes 
(<500 nm, lower left image) and giant autolysosomes 
(>1.5 µm, examples in lower middle and right images) con-
taining various compositions of densely packed undigested 
material and lipid droplets (clear round structures).
Cellular analysis shows that APP‑CTFs are cleared 
through the autophagic‑lysosomal degradation pathway
The above data suggested a role of lysosomal-autophagic 
degradation in C99 accumulation and would agree with ear-
lier data proposing a major contribution of this degradation 
pathway in APP-CTF clearance [1, 8, 54, 57]. To confirm 
the role of lysosomal enzymes in the fate of C99, we used 
SH-SY5Y neuroblastoma overexpressing APPswe (known 
to potentiate β-secretase-mediated C99 and Aβ production 
[29] and harbored by the βAPP transgene in both 2xTgAD 
and 3xTgAD mice [37]) (SH-APPswe). Clearly, treatments 
of SH-APPswe with either the lysosomotrophic weak base 
NH4Cl or specific lysosomal protease inhibitors, such as 
the cathepsin B inhibitors leupeptin and PADK or the cath-
epsin D inhibitor pepstatin A, all led to large increases in 
APP-CTFs, including the most abundantly expressed C83, 
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C99 and AICD (Fig. 2a, b). These treatments also led to 
the accumulation of other higher molecular mass APP-
CTFs, notably one about a size of 25 kDa (Fig. 2a, arrows), 
whose levels were very low in non-treated cells, show-
ing its particularly high sensitivity to lysosomal degrada-
tion. Although, we did not determine the exact identity of 
Fig. 1  C99 accumulates in enlarged cathepsin B- and lamp1-positive 
structures. a Co-immunohistochemical staining of C99 with 82E1 
(green) and α-cathepsin B (red) in 3-month-old 3xTgAD mice. Note 
the co-localization (merged image with DAPI staining) of the two 
labelings and the presence of enlarged (arrowheads) cathepsin B 
structures in 82E1-positive cells as compared to normal-sized cath-
epsin B structures (arrows) in 82E1-negative cells. Scale bar 20 μm. 
b Co-immunohistochemical staining with FCA18 (red) and α-lamp1 
(green) shows the localization of the FCA18-associated staining 
within enlarged lamp1 structures in both 14-month-old 2xTgAD 
(2AD) and 3xTgAD (3AD) mice. Scale bar 10 μm. c Electron micro-
photographs were taken from the subiculum of 14-month-old non-
transgenic (nonTg), 2AD or 3AD mice. Upper panels correspond 
to low-magnification images of representative neurons from nonTg, 
2AD or 3xTgAD mice (scale bar 5 μm). The lower images illustrate 
examples of lysosomal-dense bodies (<0.2 μm, left image), or of big-
ger membrane-limited structures of homogenous density correspond-
ing to autolysosomes (>0.5 μm, middle panels) and giant autolys-
osomes (>1.5 μm, middle and right panels)
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Fig. 2  In vitro analysis shows that APP-CTFs are degraded by cath-
epsins through autophagy. a, b SH-APPswe cells were treated with 
NH4Cl, leupeptin (Leu), pepstatin A (PepA) or PADK and analyzed 
by western blot using α-APPct. Arrows correspond to a non-identified 
25 kDa APP-CTF fragment. Bars in b correspond to quantification of 
C99 and C83 immunoreactivities obtained in a and expressed relative 
to expressions measured in DMSO-treated cells normalized to actin. 
Data are represented as mean ± SEM, as determined by ANOVA 
one-way Dunnett post hoc test, **p < 0.01 and *p < 0.05 indicate 
significant differences relative to control cells (n = 10–16, from four 
independent experiments). c Immunocytochemical analysis using 
α-APPct and α-lamp1 on H2O or NH4Cl treated SH-APPswe cells. 
Note the labeling of α-APPct in enlarged α-lamp1 vesicles in merged 
images (arrow). d SH-APPswe cells were infected with lenti-cathep-
sin B (CatB) or empty vector (mock) virus at different concentrations 
(1, 5 or 10 μl of a stock corresponding to 3.75 × 108 TU/ml) and 
CatB and APP-CTF levels were analyzed after 48 h by western blot. 
α-cathepsin B revealed immature (proCatB) and mature (mCatB) 
cathepsin B. e, f CatB and APP-CTF levels were analyzed by western 
blot in CatB stable cell lines after six passages. Bars in f represent 
the quantification of mCatB and C83 and C99 immunoreactivities 
obtained in e, each expressed as respective expressions measured in 
mock cells. Data are represented as mean ± SEM, Mann–Whitney, 
***p < 0.001 and **p < 0.01 (n = 7 from three independent experi-
ments). g Recombinant C100-flag was incubated in the absence or 
presence of increasing concentrations of purified CatB at 37 °C dur-
ing 0 (To, 50 ng) or 60 min (5,10 or 50 ng) and C100 levels were 
detected by western blot using α-Flag antibody. h, i SH-APPswe cells 
were treated with smer-28 (smer), PADK or bafilomycin A1 (BafA1), 
and APP-CTF levels were analyzed by western blot using α-APPct. 
Arrow corresponds to a non-identified 25 kDa APP-CTF fragment. 
Bars in i correspond to quantification of C83 and C99 immunoreac-
tivities obtained in h and expressed as the percentage of the expres-
sions in DMSO-treated cells normalized to actin. Data are repre-
sented as mean ± SEM, as determined by ANOVA one-way Dunnett 
post hoc test, **p < 0.01 and *p < 0.05 indicate significant differ-
ences relative to control cells n = 8, from three independent experi-
ments
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this fragment, it could possibly correspond to the recently 
described ƞ-secretase-derived APP-CTF [2, 59]. Immu-
nostaining showed that these APP-CTFs strongly accumu-
lated in lamp1-positive structures (Fig. 2c) and similarly to 
lamp1, they localized at their membranes (Fig. 2c, arrow). 
The fact that they were more numerous and much larger 
in NH4Cl-treated cells than in control cells suggested that 
many of them could represent endo- or autolysosomes 
instead of simple lysosomes (Fig. 2c). If C99 load is genu-
inely increased by a defect of the enzymatic machinery, one 
Fig. 3  In vivo treatment of 3xTgAD mice with the γ-secretase 
inhibitor ELND006 (D6) leads to increased APP-CTFs localized to 
large cathepsin B-positive structures and to autophagic impairment. 
5-month-old non-transgenic (nonTg) or 3xTgAD males were treated 
daily with D6 or vehicle by oral gavage during 1 month. a Immu-
nostaining with FCA18 in the subiculum (see insert) of 3xTgAD 
vehicle- (AD-CT) or D6-treated (AD-D6) mice. Scale bar 125 and 
20 μm, respectively. b, c RIPA-soluble (sol.) fractions from hip-
pocampi of AD-CT or AD-D6 mice were analyzed for βAPP, APP-
CTF, LC3-I, LC3-II and p62 expression by western blot. LC3-II 
was revealed after long time exposure of the same blot revealed for 
LC3-I. RIPA insoluble acid formic retrieved fractions (is) were ana-
lyzed for APP-CTF expression. Bars in c, are the mean ± SEM of 12 
animals of each treatment and represent the quantification of βAPP, 
C83, C99 and p62 immunoreactivities expressed as the percentage 
measured in AD-CT mice normalized to actin, and the LC3-II to 
LC3-I ratio normalized to AD-CT. Statistical analysis was performed 
by Mann–Whitney and ***p < 0.001 and **p < 0.01 indicate signifi-
cant differences relative to AD-CT. d, e RIPA-soluble fractions from 
hippocampi of non-transgenic vehicle- (nonTg-CT) or D6-treated 
(nonTg-D6) mice were analyzed for APP-CTF, LC3-I, LC3-II and 
p62 expression by western blot. Right lane corresponds to AD-D6 
mice. Bars in e are the mean ± SEM of six animals of each treatment 
and represent the quantification of C83 and p62 immunoreactivities 
expressed as the percentage measured in nonTg-CT mice. Statistical 
analysis was performed by Mann–Whitney and ***p < 0.001 indicate 
significant differences relative to nonTg-CT. f Images correspond to 
co-immunohistochemical staining with 82E1 and α-cathepsin B in 
subiculum of AD-D6 mice. Scale bar 20 μm
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should conversely expect to reduce C99 levels by enhanc-
ing lysosomal enzyme expression. Indeed, reduced APP-
CTF levels were observed in both lentiviral-induced cath-
epsin B overexpressing cells (Fig. 2d) and in cells stably 
expressing this enzyme (Fig. 2e, f), as compared to mock-
transfected cells. Furthermore, to demonstrate the abil-
ity of cathepsin B to catabolize C99 directly, we designed 
a bimolecular enzymatic assay in which various amounts 
of recombinant cathepsin B were incubated with recom-
binant C99 (C100-flag). This experiment confirmed the 
direct degradation of C99 by cathepsin B (Fig. 2g). Finally, 
we used a pharmacological approach to either activate or 
inhibit autophagy by using the small molecule enhancer of 
rapamycin, smer-28 [54] or the vacuolar-type H+ ATPase 
inhibitor, bafilomycin A1, respectively. As expected, APP-
CTFs levels were reduced by smer-28 and enhanced by 
both bafilomycin A1 and the cathepsin B inhibitor PADK 
(Fig. 2h, i). All together, these findings highlighted a criti-
cal role of lysosomal-autophagic function in APP-CTF 
clearance and clearly supported our hypothesis connect-
ing impaired lysosomal-autophagic degradation and C99 
accumulation.
In vivo treatment of young 3xTgAD mice with the 
γ‑secretase inhibitor ELND006 triggers massive 
increases in EAL‑associated APP‑CTFs and leads 
to autophagic pathology
We then questioned whether C99 per se could contribute 
to lysosomal-autophagic dysfunction. To this end, we took 
advantage of a pharmacological approach in which we used 
the γ-secretase inhibitor ELND006 (D6) found to induce 
enhanced C99 (and C99-derived C83) levels [24]. Young 
mice were treated daily for 1 month with D6 and analyzed 
for C99 expression by immunohistochemistry (Fig. 3a, f) or 
western blot (Fig. 3b, c) as well as for lysosomal function 
(Fig. 3b, c). As expected, FCA18-associated immunolabe-
ling showed a remarkable increase in lysosomal-associated 
C99 staining in brains of D6-treated mice (AD-D6) as com-
pared to those of vehicle-treated mice (AD-CT) (Fig. 3a). 
This pharmacological treatment also drastically enhanced 
the number of enlarged cathepsin B-positive structures in 
C99-containing neurons indicating concomitant C99 accu-
mulation and exacerbated lysosomal pathology (Fig. 3f). 
These observations were confirmed by western blot analy-
sis revealing significant increases in the autophagic marker 
LC3-II and the autophagic substrate p62/SQSTM1 (Fig. 3b, 
c), thus indicating autophagic impairment [6]. In wild-type 
(nonTg) mice, the treatment with the inhibitor also led to 
increased levels of C83, which however remained very 
low as compared to those observed in AD-D6 mice (right 
lane in the western blot) (Fig. 3d, e). In both vehicle and 
D6-treated nonTg mice, LC3-II was not detected and p62 
levels were unchanged (Fig. 3d, e) indicating the absence 
of effect of D6 on autophagic function in these mice.
In light of these observations, electron microscopy anal-
ysis (EM) was performed to confirm the above-described 
autophagic alterations. The subiculum of young AD vehi-
cle-treated mice (AD-CT) displayed some small dense 
bodies (Fig. 4a, blue arrows) and various-sized dense 
lipid-containing autophagic vacuoles (Fig. 4a, red arrows) 
localized to perikarya, while age-matched vehicle-treated 
(nonTg-CT) (Suppl. Figure 2a) or D6-treated nonTg 
(nonTg-D6) neurons (Suppl. Figure 2b) presented very few 
of such structures. In D6-treated AD animals (AD-D6), EM 
revealed a strong autophagy-related pathology and intra-
neuronal damage (Fig. 4b, d–i and Suppl. Figure 2e–j). The 
number of small dense structures (<0.5 μm, blue arrows 
“1” in Fig. 4i) was identical in AD-CT and AD-D6 mice, 
but the number of larger sized autophagic vesicles, many 
containing lipids (>0.5 μm, red arrows “2” in Fig. 4i), 
was significantly increased in AD-D6 mice. However, the 
most striking feature of the autophagy-related pathology 
was the presence of multiple large vacuoles filled with 
heterogenous non-digested cargoes and multilamellar bod-
ies (blue ML) (Fig. 4d, e–i and Suppl. Figure 2e–j—red 
arrowheads), (red arrowheads “3” in Fig. 4i), probably cor-
responding to immature autophagic vesicles [62]. Moreo-
ver, many AD-D6-treated neurons exhibited large electron-
lucent areas of the cytoplasm localizing close to autophagic 
vesicles, suggesting a link between autophagic leakage and 
Fig. 4  In vivo treatment of 3xTgAD mice with the γ-secretase inhib-
itor ELND006 (D6) leads to autophagic pathology and intraneuronal 
damage. Electron microphotographs of neuronal somas and neuropil 
from 5-month-old 3xTgAD males treated with D6 (AD-D6) (b, d, 
e, h) or vehicle (AD-CT) (a, c) during 1 month. Neuronal perikarya 
of AD-CT and AD-D6 mice contained dense lysosomal bodies (blue 
arrows) (a, b) and lipid-containing autophagic vacuoles (red arrows) 
(a), that are more abundant and enlarged in AD-D6 mice (red arrows) 
(b, e, h). The AD-D6 mice also displayed multiple large vesicles 
filled with heterogenous material (d–h—red arrowheads) and multi-
lamellar bodies (d, g—blue ML).The neuropil of AD-CT mice pre-
sented many normal appearing synaptic contacts characterized by 
typical synaptic post-densities (PSDs, yellow arrows in c) and normal 
mitochondria (black arrows). In contrast, the neuropil in AD-D6 mice 
displayed very few normal appearing synaptic contacts (d—yellow 
arrows), many damaged mitochondria (black arrows, f, g) and elec-
tron-lucent areas (h—blue stars). Scale bars are 2 μm in c, d, e, g, 
5 μm in a, b, f, and 10 μm in h. i Quantification of autophagic struc-
tures in slices from AD-CT (black bars) and AD-D6 (grey bars) mice. 
The autophagic structures (AVs) were classified in three (1–3) distinct 
groups, 1 corresponding to small dense AVs (blue arrows, less than 
1 μm), 2 to a mix of larger sized and more or less lipid-containing 
AVs (red arrows) and 3 to large vesicles containing membranous 
material and multilamellar bodies (red arrowheads). Bars correspond 
to the average number of AVs per neuron (per cross section) and a 
count of 40–50 neurons per mouse (2 mice for each condition). Data 
are represented as mean ± SEM and statistical analysis was per-
formed using the Mann–Whitney test and ***p < 0.001 indicate sig-
nificant differences relative to AD-CT
▸
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erosive destruction (Fig. 4h, and Suppl. Figure 2f, j—blue 
star). D6-treated neurons also presented a high number 
of damaged mitochondria (see examples in Fig. 4d, g and 
Suppl. Figure 2g, i—black arrows) and reduced synaptic 
contacts within the neuropil (Fig. 4d, yellow arrows), as 
compared to control mice (Fig. 4c—yellow arrows).
We next compared the effect of D6-treatment on APP-
CTF accumulation in 2xTgAD and 3xTgAD mice. This 
treatment led to same increases in C99 (and C99-derived 
C83) (Suppl. Figure 3a, b) and in punctiform staining 
(Suppl. Figure 3d) in the two strains, whereas the effect 
of D6 on Aβ load was detected only in 3xTgAD mice dis-
playing enough Aβ do detect a decrease (Suppl. Figure 3c). 
These data fully agreed with our proposal of a dual effect 
of D6 on APP-CTF accumulation, one linked to its canoni-
cal inhibitory effect of γ-secretase and one to its inhibitory 
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effect on lysosomal degradation. In agreement with defec-
tive lysosomal degradation, both D6-treated 2xTgAD and 
3xTgAD animals displayed enhanced, rather than lowered 
levels of the other γ-secretase cleavage-derived metabolite 
AICD (Suppl. Figure 3a, b) another lysosomal substrate 
(Fig. 2a) (see also [56]).
The γ‑secretase inhibitor ELND006 triggers lysosomal 
APP‑CTF accumulation, reduced cathepsin B activity 
and autophagic impairment in SH‑APPswe cells, 
but not in SH‑mock cells
To more precisely dissect the C99-mediated molecu-
lar mechanisms, we studied the effect of D6 treatment 
on lysosomal function in SH-APPswe cells. Firstly as 
expected, D6 triggered a drastic decrease in extracellu-
lar Aβ (not shown) and concomitant increase in C99 and 
C83 (Fig. 5a). Immunocytochemical analysis showed that 
these APP-CTFs were particularly abundant in lamp1-pos-
itive structures (Fig. 5b), which were enlarged and more 
numerous than those observed in control cells, similarly 
to cells treated with lysosomal inhibitors (Fig. 2c). These 
data were confirmed by Lysotracker-red, which labeled 
many and mostly large-sized puncta in D6-treated cells as 
compared to vehicle-treated cells (Fig. 5c). No increase in 
Lysotracker-red staining was seen in D6-treated SH-mock 
cells (i.e., cells only expressing endogenous levels of wild-
type APP), suggesting a strong link between lysosomal 
dysfunction and APP-CTF accumulation. In addition, four 
independent lines of data supported our hypothesis, when 
we compared the effects of D6 and DAPT (another well-
known γ-secretase inhibitor [58]) in SH-APPswe cells 
to SH-mock cells. Firstly, D6 and DAPT reduced in vitro 
cathepsin B activity (Fig. 5d) and lowered the levels of 
mature cathepsin B (Fig. 5e, f) in SH-APPswe but not in 
SH-mock cells (Fig. 5e), while NH4Cl strongly inhibited 
cathepsin B in both cell types (Fig. 5d–f). Moreover, in SH-
APPswe cells both γ-secretase inhibitors led to the accu-
mulation of a low-molecular weight (12 kDa) cathepsin B 
immunopositive product, probably corresponding to a deg-
radation product of this enzyme (CatBdg) and supporting 
defective lysosomal clearance (Fig. 5e, f). Secondly, D6 
and DAPT increased the levels of the autophagic mark-
ers LC3-II and p62 in only APPswe cells and the levels of 
these markers correlated with those of APP-CTFs (Fig. 5e, 
f). Thirdly, D6 treatment significantly increased LC3-posi-
tive vesicular profiles in SH-APPswe cells, whereas little if 
any LC3-GFP puncta were found in D6-treated SH-mock 
cells (Fig. 5g). Fourth, electron microscopy revealed the 
presence of large (0.5–2 μm) abnormal dense autolyso-
somal structures in D6-treated SH-APPswe cells, which 
structurally looked similar to those observed in leupeptin-
treated cells (Fig. 5h).
Adeno‑associated viral vector (AAV)‑mediated 
expression of C99 in wild‑type mice leads to the 
accumulation of aggregated C99 in enlarged cathepsin 
B and lamp1‑positive structures
In order to definitely demonstrate that C99 per se is suf-
ficient to induce lysosomal pathology, we used an AAV-
mediated strategy to express C99 under the transcriptional 
control of the neuron-specific synapsin I in wild-type ani-
mals. AAV-C99, AAV-GFP- or AAV-empty was injected 
into the ventricle of newborn mice and C99 expression 
was analyzed at 2 months post-AAV delivery. Western 
blot revealed a significant and specific increase of C99 
in AAV-C99 injected brains (Fig. 6a). As compared to 
AAV-GFP mice, in which GFP was observed in many 
neurons and throughout the brain (Fig. 6b, left panels), 
immunohistochemical analysis of C99 in AAV-C99 mice 
using α-APPct, showed a more restricted expression that 
was particularly high in the hippocampus and neocortex 
(Fig. 6b, right panels). Within the neurons of these areas, 
the staining was intraneuronal and membrane-associated 
giving rise to a distinct immunostaining when compared to 
that of the cytoplasmic protein GFP (Fig. 6b). To discrimi-
nate between overexpressed C99 and endogenous APP 
and APP-CTFs that are also detected with the α-APPct 
antibody (recognizing both human and mouse APP, see 
supplementary table), we compared the immunostain-
ings in AAV-C99 and AAV-empty mice. As expected, 
α-APPct detected membranous staining in many neu-
rons and throughout the brain in AAV-empty mice; how-
ever, the intensity of this staining was much lower than 
that obtained in the AAV-C99 mice, indicating that the 
largest part of this staining corresponded to exogenously 
expressed C99. To determine the exact intraneuronal stain-
ing of C99, we performed immunocytochemical staining 
of C99 in cultured transfected cells that revealed that C99 
was localized almost exclusively to the Golgi apparatus 
(Suppl. Figure 4a), whereas plasma membrane-associated 
C99 was also evident in few cells (Suppl. Figure 4b). As 
observed in SH-APPswe cells, the treatment with NH4Cl 
or D6 both led to the redistribution of APP-CTFs into 
EAL-associated structures and very little or no co-localiza-
tion with GM130 was seen in these cells (Suppl. Figure 4c, 
d). In AAV-C99 brains, α-APPct did not detect EAL-asso-
ciated staining, but interestingly when we used FCA18 or 
82E1, the staining was punctiform and looked similar to 
that observed in the 3xTgAD mice. This labeling was pre-
sent in the same brain regions labeled with α-APPct, but 
was localized to a much more restricted number of neu-
rons and most strongly in the subiculum (Fig. 6d) and in 
some layers of the cortex. Interestingly, the other N-ter-
minal-directed antibodies 6E10 and 4G8 recognized both 
the membrane-associated labeling and puncta (Fig. 6d, 
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Fig. 5  γ-Secretase inhibitor treatment triggers autophagic dysfunc-
tion in APPswe-expressing SHSY-5Y but not mock-transfected cells. 
a SH-APPswe cells were treated with ELND006 (D6) and analyzed 
for APP-CTF levels by western blot. APP-CTFs were detected using 
α-APPct, 4G8 or 6E10 (see diagram for epitope recognition) and 
compared to C99-flag expression in HEK transfected cells. b Co-
immunocytochemical staining of vehicle (Veh) or D6-treated APP-
swe cells using α-APPct and α-lamp1 shows a high overlap of these 
labelings. Scale bar 2 μm. c Vehicle (V) or D6-treated SH-mock or 
SH-APPswe cells were stained with Lysotracker red and DAPI. Scale 
bar 5 μm. d Cathepsin B (CatB) activity was monitored in vitro 
from microsomal fractions of SH-APPswe cells treated with vehi-
cle (V), D6, DAPT (DT) or NH4Cl (NH4). Data are represented as 
mean ± SEM, as determined by ANOVA one-way Dunnett post hoc 
test, ***p < 0.001 indicate significant differences relative to control 
cells (vehicle-treated cells), n = 8–14 from 2 independent experi-
ments. e, f Stably CatB expressing mock or APPswe cells were 
treated with vehicle (V), D6, DAPT (DT) or NH4Cl and western blot 
analysis was used to determine the levels of βAPP and APP-CTFs, 
LC3-I, LC3-II, p62, CatB and actin. Besides the detection of the 
30 kDa immunoreactivity corresponding to mature CatB, the CatB 
antibody revealed immunoreactivity at about 12 kDa most probably 
corresponding to a degradation product of this enzyme (CatB-dg.). f 
Quantification of immunoreactivities obtained in e for APPswe cells 
were normalized to actin and expressed as the percent of expression 
levels obtained in control treated cells. g SH-mock or SH-APPswe 
cells were transfected with LC3-GFP, treated with vehicle or D6 and 
was visualized by fluorescence microscopy. Scale bar 5 μm. h Elec-
tron microphotographs show representative cells from each condition. 
Scale bars are 1 or 2 μm, as indicated
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e—arrow and arrowhead, respectively) suggesting the 
presence of two distinct C99 species. Since, the lysoso-
mal-associated staining required formic acid retrieval and 
since C99 has been shown to have a high tendency to self-
aggregate and form amyloid-like fibrils in vitro [30, 60], 
we hypothesized that the C99 accumulating in lysosomes 
could correspond to aggregated or misfolded forms that 
would not be detected with C-terminal-directed antibodies 
because of aggregation-dependent structural or conforma-
tional changes of the C-terminal moiety. In agreement with 
this hypothesis, we found that the punctiform staining was 
also detected with the aggregate-specific antibody NU1 
[23] (Fig. 6d). As observed in the 3xTgAD mice, these 
aggregates were localized to enlarged cathepsin B- and 
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lamp1-positive structures (Fig. 6f, g) and the number and 
size of such enlarged structures was enhanced in the AAV-
C99 mice, as compared to AAV-empty mice (Fig. 6h).
ELISA showed that C99-expressing mice do produce 
Aβ, corresponding mainly to Aβ40 but only very low lev-
els of the aggregation-prone Aβ42 (Fig. 6c). Therefore, 
one could not exclude the possibility, that in this model, 
the punctiform staining could correspond to aggregated 
Aβ, instead of C99. Thus, to rule out this possibility, the 
C99-expressing mice were treated with D6. As described 
for 3xTgAD mice, γ-secretase inhibition enhanced the 
levels of C99 and C99-derived C83 [16] (Fig. 7a, but see 
also Fig. 8b) and strongly reduced Aβ levels (Fig. 7b). 
Immunohistochemical analysis using NU1 showed an 
increased rather than decreased punctiform immunostain-
ing in D6-treated mice, clearly indicating that this staining 
should be accounted for C99 and not Aβ (Fig. 7c). Simi-
lar enhanced punctiform staining was observed with other 
N-terminal directed antibodies, 82E1 (Fig. 8a), FCA18, 
6E10 (not shown) and 4G8 (Fig. 7d). In D6-treated mice, in 
areas expressing particular high punctiform staining, NU1 
and 4G8 also gave rise to an extracellular diffuse staining 
surrounding the neurons (Fig. 7c, d, respectively), prob-
ably corresponding to the release of intraneuronal mate-
rial from dying neurons (see also below). We also used 
α-APPct to analyze the effect of D6-treatment (Fig. 7c, 
e) and found that, within the subiculum, D6 also led to a 
strong APP-CTF associated staining localizing to syn-
aptic regions (note the high overlap of α-APPct and the 
presynaptic marker synaptophysin in D6 treated AAV-C99 
mice (Fig. 7e). The low intensity of α-APPct labeling in 
D6-treated AAV-empty mice showed that these synaptic 
localized APP-CTFs were mostly linked to viral-mediated 
C99. These observations confirmed the presence of two 
species of C99 (APP-CTFs), one non-aggregated and rec-
ognized by α-APPct and one aggregated and detected with 
N-terminal- and aggregate-specific antibodies. D6 treat-
ment led to increased levels of both non-aggregated APP-
CTFs localizing in presynaptic regions and of aggregated 
APP-CTFs accumulating in lysosomal-derived structures. 
It is noteworthy that similar D6-induced increases in both 
synaptophysin-positive APP-CTFs (Suppl. Figure 5a, d–e) 
and NU1-labeled aggregated APP-CTFs (Suppl. Figure 5b) 
was found in 3xTgAD mice, thus ruling out the possibil-
ity of artificial routing of C99 in the C99-expressing mice 
model. Moreover, western blot analysis confirmed the 
accumulation of C99 and C83 in both microsome- and 
synaptosome-enriched fractions of hippocampi from D6 
treated 3xTgAD mice (suppl. Figure 5c).
Furthermore, and more surprisingly, in the C99-express-
ing mouse, D6 not only led to an enhanced staining in the 
cortex and subiculum, the two main regions expressing 
C99, but it also induced a strong immunostaining in vari-
ous other brain regions, in which very low or no C99 stain-
ing was seen in vehicle-treated AAV-C99 mice (Fig. 7f), 
but in which GFP expression was high in AAV-GFP mice 
(Fig. 6b, left panels). Again, the labeling obtained with 
N-terminal antibodies was punctiform and in some regions 
also diffuse and extracellular. Taken together, these findings 
clearly demonstrated that this labeling should be ascribed 
to C99 and not to Aβ. Ηowever, they also suggested that 
these regions display either high γ-secretase activity or 
alternative D6-sensitive C99 degradation, explaining the 
absence of C99 labeling in vehicle-treated C99-expressing 
mice.
D6 treatment not only leads to autophagic dysfunction 
but also to inflammatory responses and synaptic defects 
in C99‑expressing mice, but not in wild‑type mice
As described above, C99 accumulated in enlarged cath-
epsin B- and lamp1-positive structures and particularly 
within the subiculum in C99-expressing mice. In brains 
from D6-treated AAV-C99 mice, the number of neurons 
displaying such enlarged structures was increased rather 
than decreased (Fig. 8a). Furthermore, these brains dis-
played elevated levels of the autophagic marker LC3-
II (Fig. 8b, c), while this was not the case in those from 
D6-treated AAV-GFP mice (Fig. 8d), again indicating that 
these lysosomal alterations were linked to C99 expression. 
Fig. 6  In vivo adeno-associated viral vector (AAV)-mediated expres-
sion of C99 in wild-type mice leads to the accumulation of aggre-
gated C99 in enlarged cathepsin B-positive structures. 2-month-old 
AAV-empty, AAV-GFP or AAV-C99 were analyzed by western blot 
(a) or immunohistochemistry (b). a RIPA-soluble fractions from 
forebrain hemispheres were analyzed for APP-CTF expression using 
either α-APPct or 6E10. b GFP fluorescence was observed in AVV-
GFP mice using a confocal microscope and C99 expression was 
visualized after immunohistochemical staining with α-APPct and 
using AAV-empty mice as a negative control. The lower panel shows 
higher magnification images at the level of the boxed areas high-
lighting the different subcellular labeling of GFP and C99. c Bars 
correspond to ELISA measurement of Aβ40 and Aβ42 in soluble 
(sol) and insoluble (is) fractions, respectively, and are represented as 
mean ± SEM n = 6 animals. d Images from immunohistochemical 
analysis of C99-associated expression in C99-AAV mice at the level 
of the subiculum using α-APPct, FCA18, 6E10, 4G8 or NU1. Scale 
bar 25 μm. e High-magnification images of co-immunolabeling with 
α-APPct and 4G8 illustrating the intraneuronal membrane-associated 
(arrow) and punctiform (arrowhead) stainings. Scale bar 5 μm. f, g 
Co-labeling of 82E1 and cathepsin B (f) or 4G8 and lamp1 (g) shows 
that C99 localizes to enlarged EAL-associated structures (arrow-
head in merged images). Scale bar 25 and 5 μm, respectively. h 
Quantitative analysis of lamp1 structures in the subiculum of AAV-
empty or AAV-C99 mice. Data are represented as the relative num-
ber per cell (counts (a.u)/cell) and average size of lamp1-positive 
puncta expressed as arbitrary units (a.u). Data are represented as 
mean ± SEM and are from two AAV-empty and two AAV-C99 mice, 
three brain slices for each animal and six images each slice. Images 
show representative images of lamp1 staining
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Moreover, as described above, in some regions in which 
lysosomal-associated C99 was abundant, 4G8 also unrave-
led an important and diffuse extracellular staining likely 
corresponding to the release of intracellular material from 
dying neurons (Fig. 8e, f, but see also Fig. 7c, d). In agree-
ment with necrotic cell death, nuclear staining with DAPI 
or Cresyl violet revealed the presence of many pycnotic 
nuclei (Fig. 8e, f). The same regions also displayed an 
increased number of both Iba-1-positive microglia (Fig. 8g) 
and GFAP-positive astrocytes (Fig. 8h). Iba-1 labeling 
was enhanced by the sole expression of C99 (compare 
AAV-C99 and AAV-empty) and further enhanced by D6 
treatment, indicating concomitant C99 accumulation and 
inflammatory responses (Fig. 8g). Importantly, microglial 
271Acta Neuropathol (2016) 132:257–276 
1 3
and astrocytic activation (Fig. 8h) were not induced by D6 
in AAV-empty mice. Finally, we assessed the effects of 
C99 expression on synaptic function by measuring long-
term potentiation (LTP) at the CA1 pyramidal neurons to 
subicular neurons in AAV-empty or AAV-C99 vehicle or 
D6-treated mice (Fig. 8i–k). Whereas no differences were 
seen in basal synaptic transmission between AAV-empty, 
AAV-C99 vehicle or D6-treated mice (Fig. 8i), only the 
AAV-empty mice displayed a robust induction in LTP 
(Fig. 8j, k). D6 did not worsen LTP alterations, but this 
could be due to the drastic floor effect of C99 over-expres-
sion alone. However, the fact that D6 did not reverse synap-
tic dysfunction indicated that it was not caused by Aβ, but 
should be directly linked to C99.
Discussion
Recently, we showed that the 3xTgAD mouse model 
develops an early, age-dependent intraneuronal accumula-
tion of the β-secretase-derived βAPP fragment C99 [24]. 
In the present work, we demonstrate a link between this 
accumulating C99 and endosomal-autophagic-lysosomal 
(EAL) pathology. Firstly, the comparison of 2xTgAD 
(harboring wild-type PS1) and 3xTgAD mice (harboring 
PS1M146V) revealed that C99 accumulation was the con-
sequence of impaired lysosomal-autophagic function rather 
than of altered γ-secretase processing and in agreement 
with this, C99 was found to accumulate within endolyso-
somal/autolysosomal structures in both of these mice. 
Moreover, our in vitro data and earlier work [1, 8, 57] dem-
onstrated a major role of the lysosomal-autophagic path-
way in C99 degradation. The 3xTgAD mice harbor PS1 
and tau mutations, and the 2xTgAD mice harbor mutated 
tau, which possibly could have interfered with C99/APP 
trafficking and degradation, as described for some PS1 
and tau mutants [25, 63]. Therefore, to determine whether 
EAL-associated C99 accumulation could be seen also in 
a model devoid of any mutated transgenes, we generated 
a viral-based C99-expressing transgenic model. Interest-
ingly, in these mice immunohistochemical studies revealed 
the presence of two clearly distinct C99 species. One of it 
was intraneuronal membrane-associated and mainly local-
izing to the golgi apparatus. This C99 was recognized by 
α-APPct and representing the major part of C99. Another 
one was localized to EAL structures and restricted to a 
subgroup of the neurons. This C99 was aggregated or mis-
folded and recognized by both N-terminal-directed and 
aggregate-specific antibodies. Also in these mice, many 
of the C99-accumulating EAL vesicles were enlarged, 
again implying a link between C99 and EAL pathology. 
Taken together, these data ruled out the possibility that C99 
aggregation and lysosomal localization was linked to arti-
ficial cellular trafficking caused by the expression of other 
mutated transgenes or to a putative lack of adequate target-
ing of exogenously expressed C99. We cannot exclude that 
the overexpression of these proteins itself could also have 
influenced degradation, but importantly elevated C99 levels 
have also been reported in human AD post-mortem brains 
[18, 22, 42], indicating that C99 accumulation is not spe-
cific to mouse AD models, but also do occur in human AD.
The EAL-associated C99 was recognized by the aggre-
gate-specific antibody NU1 and localized to the mem-
branes of these vesicles. We therefore hypothesized that 
this aggregated or misfolded C99 itself could also be a 
trigger of lysosomal/autophagic dysfunction. To validate 
this hypothesis, we took advantage of a pharmacological 
approach in which 3xTgAD or C99-expressing mice were 
treated with the γ-secretase inhibitor, ELND006 (D6) that 
enhances C99 levels [24]. Indeed, in both mouse models, 
D6 treatment increased EAL-associated C99 levels and led 
to exacerbated pathology: elevated levels of the autophagic 
markers LC3-II and p62, increased number of abnormal-
sized C99-positive cathepsin B- and lamp1-structures and 
a higher density of non-digested autophagic vesicles high-
lighted by electron microscopy. Ultrastructural analysis 
also revealed the presence in neuropil of large autophagic 
vesicles filled with aberrant storage material likely cor-
responding to immature AVs, suggesting that, in addition 
to the effect on lysosomal proteolysis, γ-secretase inhibi-
tion also led to disturbed AV maturation and/or transport. 
Importantly, these effects of D6 were not observed in wild-
type animals, strongly suggesting that they were dependent 
Fig. 7  γ-Secretase inhibitor treatment of AAV-C99 expressing mice 
leads to increased accumulation of aggregated APP-CTFs within lys-
osomal-autophagic vesicles. AAV-C99 and AAV-empty injected mice 
were treated daily for 12 days with ELND006 (D6) or vehicle (V). 
a RIPA-soluble fractions of forebrain hemispheres were analyzed 
by western blot for APP-CTF expression using α-APPct or 6E10. 
b ELISA analysis of Aβ40 levels in RIPA-soluble- (sol) and for-
mic acid retrieved (is) hemisphere fractions. Data are represented as 
mean ± SEM. Statistics were performed with the Mann–Whitney test 
by comparing soluble and insoluble fractions separately,**p < 0.01 
(n = 6). c Images from immunofluorescence staining of brain slices 
from vehicle- (AAV-C99V) or D6-treated (AAV-C99 D6) AAV-C99 
mice at the level of the subiculum using either NU1 or α-APPct. The 
lower panels correspond to high-magnification of the boxed areas. 
Scale bar is 125 and 20 μm, respectively. d Immunohistochemical 
staining with 4G8 of brain slices from AAV-C99V or AAV-C99 D6 
mice using peroxidase/DAB development (brown staining). Scale 
bar is 20 μm. e Co-immunostaining of α-APPct and α-synaptophysin 
(α-Syn) revealed a high overlap within the subiculum of AAV-
C99-D6 mice, but not in D6-treated AAV-empty mice (left panel). 
Scale bar is 5 μm. f Immunohistochemical staining of brain slices 
of AAV-C99 V (upper panels) or AAV-C99 D6 (lower panels) mice 
using α-APPct, 4G8 and NU1. Middle and right panels correspond 
to medium- and high-magnification images of NU1 labeling at the 
level of the boxed areas. Note the vesicular membrane-like staining 
of NU1 in right panel (arrowheads). Nuclei were stained with DAPI. 
Scale bar is 2.5 μm
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on APP-CTF accumulation. This was confirmed in an 
in vitro neuroblastoma model, since D6 led to autophagic 
impairment in APPswe overexpressing cells (SH-APPswe), 
but not in cells only expressing endogenous levels of APP 
(SH-mock).
Overall, the above set of data unveiled a pathological 
loop in which C99 accumulation was not only the result 
of altered autophagy, but could also be the cause of it. The 
observations that aggregated C99 accumulated within the 
membranes of the EAL vesicles suggested that it likely 
interfered directly with EAL function by perturbating 
membrane integrity and inhibiting normal lysosomal pro-
teolysis. Possibly exacerbated C99 accumulation could 
also lead to the leakage of catabolic contents, lysosomal 
enzymes and acidity into the cytoplasm and to resulting 
neuronal cell death [17, 28]. Indeed, both electron micros-
copy and immunohistochemical analysis revealed clear 
signs of neuronal necrosis and release of aggregated C99 
(and C99-derived C83) to extracellular spaces. Strikingly, 
recent papers described similar deleterious effects of EAL-
associated Aβ42 in a transgenic Aβ42-expressing dros-
ophila model [26–28], suggesting that whatever the nature 
of the aggregates, their accumulation within EAL-vesicle 
membranes could disturb lysosomal-autophagic function. 
In the D6-treated AAV-C99 mice, C99 accumulation was 
also associated with strong inflammatory responses includ-
ing both microglial activation and astrogliosis. These find-
ings showed that the pathology observed in the C99 mice 
resembled that seen in lysosomal storage disorders, in 
which a primary defect of lysosomal function induces both 
autophagic impairment and the activation of the immune 
system as a response to the accumulation of storage mate-
rial and/or dying neurons [44]. Interestingly, we also 
observed that C99 expression strongly affected synaptic 
function. Long-term potentiation recordings in the subicu-
lum of the AAV-injected mice, showed an almost complete 
absence of LTP in the subiculum of C99-expressing mice. 
D6 did not reverse this effect clearly indicating that it was 
linked to C99 expression itself and not to Aβ.
Altogether, our data showed a direct and clearly 
Aβ-independent detrimental effect of C99 and provide new 
molecular explanations for earlier mechanistically unsolved 
studies describing APP-CTF-linked toxicity. For instance, 
it was reported that the conditional knock-out of preseni-
lin1 in mice led to a progressive development of synaptic 
and cognitive alterations that were temporally correlated 
with APP-CTF accumulation [48]. Moreover, the treatment 
with γ-secretase inhibitors was found to induce both long-
term deficits and APP-CTF accumulation in mice [31, 52] 
and to accelerate cognitive decline in human [15]. Con-
sistent with these findings, the work from the group of Dr 
d’Adamio showed that the inhibition of β-secretase but not 
of γ-secretase led to reduced synaptic/memory defects in a 
mouse model of familial dementia [53]. Finally, the trans-
genic overexpression of BACE-1 in mice was observed to 
induce a pathogenic pathway involving the accumulation of 
APP-CTFs but not of Aβ [46]. Recent work from the group 
of Dr Nixon proposed a direct link between C99 accumu-
lation and endocytic abnormalities in fibroblasts derived 
from Down’s syndrome patients [20, 22], but these studies 
did not investigate the downstream effects of C99 accumu-
lation on lysosomal and autophagic function.
This work is the first to demonstrate the presence of 
two structurally and immunologically distinguishable C99 
species, one corresponding to non-aggregated and intra-
neuronal membrane-bound C99 and one to aggregated or 
misfolded C99 localized to EAL-vesicle membranes. The 
pharmacological inhibition of γ-secretase led to drastic 
increases in both non-aggregated C99 accumulating within 
synaptic regions, and in aggregated EAL-associated C99. 
These findings therefore reconciliate previous works dem-
onstrating different localizations of APP-CTFs. Whereas 
some studies reported presynaptic APP-CTF accumulation 
after γ-secretase inhibition [5, 31] or in presenilin knock-
out mice [48], others found lysosomal APP-CTF accumula-
tion in presenilin-invalidated cultured cells [14].
Altogether, our findings add a new toxic trigger to the 
amyloid cascade, which could underlie some of the AD-
related hallmarks occurring especially in the early stages of 
the disease. In the 3xTgAD mouse, the intraneuronal C99 
accumulation occurs earlier and is more important than that 
Fig. 8  γ-Secretase inhibitor treatment of AAV-C99 expressing mice 
leads to exacerbated autophagic dysfunction, inflammatory responses 
and synaptic dysfunction. a Brain slices at the levels of the subicu-
lum from vehicle- (Veh) or D6-treated AAV-C99 mice were immu-
nostained with 82E1 and α-CatB. Scale bar 25 μm. b–d Western 
blot analysis of RIPA-soluble fractions from AAV-C99 injected 
mice (b, c) or AAV-GFP mice (d) treated with D6 or vehicle (Veh). 
Brains were analyzed for APP-CTF (using either α-APPct or 6E10) 
or LC3-I/LC3-II expression. Bars in c correspond to the quantita-
tive analysis of LC3-II, expressed as the LC3-II/LC3-I ratio, and are 
relative to control (AAV-C99-Veh). Mann–Whitney test, p < 0.001, 
n = 8. Right lane corresponds to AAV-C99 mice. e, f Immunostaining 
with 4G8 or NU1 of D6-treated AAV-C99 brains using fluorescence 
(e) or peroxidase-DAB labeling (f). Note the extracellular stain-
ing (white arrows in e and black arrows in f) surrounding pycnotic 
nuclei visualized by DAPI (e, white arrowheads) or Cresyl violet (f, 
black arrowheads). Scale bars 50 or 10 μm, respectively. g, h Immu-
nostaining with 4G8, Iba1 (g) or GFAP (h) reveals both microglial 
and astrocytic activation in D6-treated mice within brain regions 
expressing important APP-CTF levels. Scale bar 300 and 50 μm, 
respectively. i Basal synaptic transmission in AAV-empty, vehicle-
treated AAV-C99 or D6-treated AAV-C99 mice (n = 2–3 slices per 
mouse from 6 to 7 mice per group. All values are mean ± SEM. j 
Field excitatory postsynaptic potential (fEPSP) slopes in subicu-
lum (n = 2–3 slices per mouse from 6 to 7 mice per group). k Sum-
mary graph of LTP magnitudes calculated 40 to 60 min after high-
frequency stimulation from graphs in (j) with statistical analysis 
(*p < 0.05; one-way ANOVA with the Tukey’s post hoc test). Error 
bars represent SEM
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of Aβ and in the AAV-C99 mice, the aggregation-prone Aβ42 
is only produced in very low amounts, compared to that of 
Aβ40. These findings might explain the major contribution of 
C99 to the observed phenotypes in our models, but of course 
we do not exclude the contribution of Aβ to the pathology. 
Finally, our data also show a region-specific accumulation of 
C99, indicating differences in proteolytic processing and deg-
radative mechanisms within neuronal subtypes. These differ-
ences could explain the accumulation of distinct catabolites in 
specific neuronal populations and underlie mechanisms con-
tributing to neuronal susceptibility to AD-related pathology. 
Taken together, our study demonstrates that C99 can partici-
pate to lysosomal pathology in the absence of Aβ.
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